RecruitingPhase 4NCT05208190
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
Sponsor
New York State Psychiatric Institute
Enrollment
280 participants
Start Date
Mar 17, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs antipsychotic treatment as usual (TAU) for reducing the risk of violent acts in real-world settings
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria5
- Diagnostic and Statistical Manual-5 (DSM-5) diagnosis of schizophrenia or schizoaffective disorder by the Structured Clinical Interview for DSM-5 (SCID-5)
- commission of a minor or serious act of violence as measured by the MCVI in the last six months
- willing and able to provide informed consent
- medically stable in judgment of physician providing study treatment
- appropriate for treatment with either clozapine or TAU, i.e., that there is clinical equipoise between the two treatment options. Individuals who are currently medication free or on any antipsychotic, with the exception of clozapine or long-acting injectable medication with a dosing interval of more than 30 days will be eligible
Exclusion Criteria6
- An unstable of serious medical or neurological condition including a myeloproliferative disorder or condition that surprises the bone marrow
- A history of intolerance/allergy to clozapine (e.g., agranulocytosis, small bowel obstruction, or myocarditis)
- A history of intellectual impairment
- pregnant or lactating women; women who are able to become pregnant but who are not willing to sue effective methods of birth control
- Individuals who score a 3, 4, or 5 within the previous month on the suicidal ideation section of the Columbia Suicide Severity Rating Scale (CSSRS), have any suicidal behavior (not including Not Suicidal Self Injury) within the previous 3 months, or are, in the opinion of the investigator, at too high of a risk for suicide to be safety treated in a randomized trial in which they may not be treated with clozapine
- Documented intolerance to or lack of any therapeutic benefit with clozapine after a full trial
Interventions
DRUGClozapine
treatment will occur naturalistically, as per standard clinical guidelines
DRUGtreatment as usual
naturalistic treatment with any other antipsychotic medication except clozapine
Locations(7)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05208190
Related Trials
Tolerability of MDMA in Schizophrenia
NCT057703751 location
Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
NCT037940761 location
Cerebellar Stimulation and Cognitive Control
NCT032171101 location
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
NCT0688278555 locations
Cerebellar Modulation of Cognition in Psychosis
NCT061077642 locations